

# Stanford

---



## Saad A. Khan, MD

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

### CLINICAL OFFICES

900 Blake Wilbur Dr

3rd Fl MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 724-1445

### Bio

---

#### BIO

Saad A. Khan, MD is a medical oncologist focused on the treatment of head and neck, thyroid and lung cancers. His research interests include therapeutic clinical trials as well as mechanisms of reducing toxicities that patients experience. His research activities include ongoing clinical trials of targeted and immune therapy in aggressive thyroid malignancies. He is a member of the NRG Head and Neck Committee, the ECOG Head and Neck Core and Thoracic Committees and the National Cancer Institute's Head and Neck Steering Committee Rare Tumor Task Force.

When not in clinic or the hospital he enjoys spending time with his family and 3 children, hiking and sitting on the beach.

#### CLINICAL FOCUS

- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

#### PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2015)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2012)
- Fellowship: Temple University Cancer Center Hematology and Oncology Fellowship (2012) PA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2009)
- Residency: University of Massachusetts Internal Medicine Residency (2009) MA
- Clinical Post-Doctoral Fellow, Temple University-Fox Chase Cancer Center, Philadelphia, PA (2012)
- Internship: Mayo Clinic General Surgery Residency (2006) MN
- Resident, University of Massachusetts Medical Center, Worcester, MA (2009)
- Medical Education: Faisalabad Medical University (2003) Pakistan

- Internship, Mayo Graduate School of Medical Education, Rochester, MN (2006)
- MD, Punjab Medical College, Faisalabad, Pakistan (2003)

## Research & Scholarship

---

### CLINICAL TRIALS

- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer, Recruiting
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients, Recruiting

## Publications

---

### PUBLICATIONS

- **Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers.** *Surgical pathology clinics*  
Palsgrove, D., Allahabadi, S., Khan, S. A.  
2021; 14 (1): 151–63
- **Survivin expression and impact on head and neck cancer outcomes.** *Oral oncology*  
Khan, S. A., Burke, M., Zhu, F., Yang, D., Dubyk, C., Mehra, R., Lango, M. J., Ridge, J. A., Sher, D. J., Burtness, B.  
2020; 112: 105049
- **Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.** *The oncologist*  
Bendell, J. n., Sharma, S. n., Patel, M. R., Windsor, K. S., Wainberg, Z. A., Gordon, M. n., Chaves, J. n., Berlin, J. n., Brachmann, C. B., Zavadovskaya, M. n., Liu, J. n., Thai, D. n., Bhargava, et al  
2020
- **A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).**  
Rischin, D., Boyer, M. J., Brzezniak, C. E., Colevas, A., Doebele, R., Gilbert, J., Gitlitz, B., Khan, S. A., Mehra, R., Seiwert, T. Y., Kroll, S., Pearce, T. E., Liu, et al  
AMER SOC CLINICAL ONCOLOGY.2016